Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

CAPS Rating: 1 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar pchop12316 (83.08) Submitted: 11/12/2014 10:37:36 AM : Underperform Start Price: $21.20 AEGR Score: +2.36

down before any up

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 11/9/2014 11:49:17 PM : Underperform Start Price: $21.29 AEGR Score: +2.88

It's been a long way down for Aegerion from highs close to 100 in late 2013, and there's a good chance that the bad times are far from over. Lomitapide's performance has been a major disappointment, as it appears Aegerion overestimated the number of HoFH patients in the market and also the number who would discontinue the drug due to side effects. Meanwhile, management has gone from claiming that the new PCSK-9 drugs, expected in mid-2015, wouldn't be useful for HoFH to claiming that even though they will take market share from lomitapide, they will somehow expand the overall patient pool.

Aegerion's revenue numbers and projections are looking bad, and management didn't take advantage of the good times to secure a future pipeline through acquisitions. The belated purchase of Myalept from AstraZeneca after the recent post-earning plunge seems like a desperate attempt by management to restore credibility. Nevertheless, the move has earned mostly raspberries from expert commentators. Unless one trusts management's ability to see unrecognized potential in Myalept, it seems like there's a good chance that Aegerion could follow Dendreon down into the vortex of negative cash flow, debt, and impending bankruptcy. But why trust management after they clearly missed the boat on lomitapide?

Recs

0
Member Avatar mdriver78 (61.78) Submitted: 9/17/2014 1:38:19 PM : Outperform Start Price: $29.54 AEGR Score: -37.42

Rule 5635(c)(4) notification for exercize price of Company Insider Options.

Recs

0
Member Avatar Irene8777 (< 20) Submitted: 7/6/2013 5:43:32 AM : Outperform Start Price: $71.49 AEGR Score: -96.98

STOCK WENT UP BY 350 PERCENT IN TWO YEARS.

Recs

1
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:01:48 PM : Outperform Start Price: $31.40 AEGR Score: -69.43

With AEGR focused on an orphan drug with no alternative treatments available and only a single potential competitor that has significant side effects, AEGR becomes a compelling buy.

Recs

0
Member Avatar CarlosDK (20.29) Submitted: 1/16/2013 2:05:22 PM : Underperform Start Price: $27.26 AEGR Score: +63.56

stockcon short

Recs

0
Member Avatar IBDContrarian (25.32) Submitted: 12/18/2012 10:42:41 AM : Underperform Start Price: $23.00 AEGR Score: +51.65

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 6 97 --B+, NO EARNINGS

Recs

1
Member Avatar EvilEmpire (28.85) Submitted: 7/25/2012 7:04:34 PM : Outperform Start Price: $14.12 AEGR Score: -3.26

PDUFA + BB

Results 1 - 8 of 8

Featured Broker Partners


Advertisement